Hypothalamic obesity after craniopharyngioma: Mechanisms, diagnosis, and treatment

92Citations
Citations of this article
94Readers
Mendeley users who have this article in their library.

Abstract

Obesity is a common complication after craniopharyngioma therapy, occurring in up to 75% of survivors. Its weight gain is unlike that of normal obesity, in that it occurs even with caloric restriction, and attempts at lifestyle modification are useless to prevent or treat the obesity. The pathogenesis of this condition involves the inability to transduce afferent hormonal signals of adiposity, in effect mimicking a state of CNS starvation. Efferent sympa- thetic activity drops, resulting in malaise and reduced energy expenditure, and vagal activity increases, resulting in increased insulin secretion and adipogenesis. Lifestyle intervention is essentially useless in this syndrome, termed "hypothalamic obesity." Pharmacologic treatment is also difficult, consisting of adrenergics to mimic sympathetic activity, or sup- pression of insulin secretion with octreotide, or both. Recently, bariatric surgery (Roux-en-Y gastric bypass, laparoscopic gastric banding, truncal vagotomy) have also been attempted with variable results. Early and intensive management is required to mitigate the obesity and its negative consequences. © 2011Lustig.

Cite

CITATION STYLE

APA

Lustig, R. H. (2011). Hypothalamic obesity after craniopharyngioma: Mechanisms, diagnosis, and treatment. Frontiers in Endocrinology. https://doi.org/10.3389/fendo.2011.00060

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free